Sino Biopharm CEO Eric Tse on Outlook, Asian Pharmaceutical Market & Trump

The transcript discusses the transition of the Chinese pharmaceutical market from generics to innovation, emphasizing globalization and market expansion. It highlights opportunities in the Pan Asia market and the challenges of conducting clinical trials. The speaker also addresses M&A activities, licensing agreements, and the impact of government reforms and tariffs on the industry.

What challenges does the company face regarding FDA skepticism towards Chinese data?

What strategies is the company considering for entering the global market?

How does the company plan to adapt to potential tariffs imposed by the U.S. government?